NUVECTIS PHARMA INC (NVCT) Stock Price, Quote, News and Overview
NASDAQ:NVCT - Nasdaq - US67080T1088 - Common Stock - Currency: USD
NVCT Quote, Performance and Key Statistics
7.78
+0.05 (+0.65%)
The current stock price of NVCT is 7.78 USD. In the past month the price increased by 0.91%. In the past year, price increased by 12.1%.
NVCT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.53 | 336.11B | ||
| AMGN | AMGEN INC | 14.77 | 164.85B | ||
| GILD | GILEAD SCIENCES INC | 15.01 | 144.54B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 120.61B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.71 | 60.80B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 42.87B | ||
| ARGX | ARGENX SE - ADR | 102.95 | 36.23B | ||
| ONC | BEONE MEDICINES LTD-ADR | 7.43 | 31.54B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.72B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 21.29B | ||
| INSM | INSMED INC | N/A | 19.72B | ||
| BIIB | BIOGEN INC | 8.31 | 19.27B |
Related stock screener links
About NVCT
Company Profile
Nuvectis Pharma, Inc. is a preclinical stage biopharmaceutical company. The company is headquartered in Fort Lee, New Jersey and currently employs 13 full-time employees. The company went IPO on 2022-02-04. The firm is developing two drug candidates: NXP800 and NXP900. NXP800 is a small molecule GCN2 activator, which is in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP800 activates the GCN2 kinase inducing inhibition of cap-dependent protein translation and activation of the integrated stress response leading to cancer cell death. NXP900 is a targeted-therapy, small molecule drug candidate that inhibits the proto-oncogene c-Src (SRC) and YES1 kinases, which is undergoing a Phase 1a dose escalation study. SRC is aberrantly activated in many cancer types, including solid tumor cancers such as breast, colon, prostate, pancreatic and ovarian cancers.
Company Info
NUVECTIS PHARMA INC
1 Bridge Plaza, Suite 275
Fort Lee NEW JERSEY US
Employees: 13
Phone: 13608377232
NUVECTIS PHARMA INC / NVCT FAQ
What is the stock price of NUVECTIS PHARMA INC today?
The current stock price of NVCT is 7.78 USD. The price increased by 0.65% in the last trading session.
What is the ticker symbol for NUVECTIS PHARMA INC stock?
The exchange symbol of NUVECTIS PHARMA INC is NVCT and it is listed on the Nasdaq exchange.
On which exchange is NVCT stock listed?
NVCT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for NUVECTIS PHARMA INC stock?
11 analysts have analysed NVCT and the average price target is 19.38 USD. This implies a price increase of 149.1% is expected in the next year compared to the current price of 7.78. Check the NUVECTIS PHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NUVECTIS PHARMA INC worth?
NUVECTIS PHARMA INC (NVCT) has a market capitalization of 183.84M USD. This makes NVCT a Micro Cap stock.
How many employees does NUVECTIS PHARMA INC have?
NUVECTIS PHARMA INC (NVCT) currently has 13 employees.
What are the support and resistance levels for NUVECTIS PHARMA INC (NVCT) stock?
NUVECTIS PHARMA INC (NVCT) has a support level at 7.68 and a resistance level at 7.84. Check the full technical report for a detailed analysis of NVCT support and resistance levels.
Should I buy NUVECTIS PHARMA INC (NVCT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NVCT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NVCT, evaluating the profitability, health, valuation and growth aspects
- NUVECTIS PHARMA INC (NVCT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NUVECTIS PHARMA INC (NVCT) Sales and EPS estimates to see what analysts future expectations are.
- NUVECTIS PHARMA INC (NVCT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NUVECTIS PHARMA INC (NVCT) Insider and Institutional Ownership to learn about the owners and their transactions.
- NUVECTIS PHARMA INC (NVCT) Stock Chart to make your own analysis
- NUVECTIS PHARMA INC (NVCT) Latest news and press-releases to stay up to date.
Does NUVECTIS PHARMA INC (NVCT) stock pay dividends?
NVCT does not pay a dividend.
When does NUVECTIS PHARMA INC (NVCT) report earnings?
NUVECTIS PHARMA INC (NVCT) will report earnings on 2025-08-06.
What is the Price/Earnings (PE) ratio of NUVECTIS PHARMA INC (NVCT)?
NUVECTIS PHARMA INC (NVCT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.13).
What is the Short Interest ratio of NUVECTIS PHARMA INC (NVCT) stock?
The outstanding short interest for NUVECTIS PHARMA INC (NVCT) is 21.04% of its float. Check the ownership tab for more information on the NVCT short interest.
NVCT Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to NVCT. When comparing the yearly performance of all stocks, NVCT is a bad performer in the overall market: 81.02% of all stocks are doing better.
NVCT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NVCT. While NVCT has a great health rating, there are worries on its profitability.
NVCT Financial Highlights
Over the last trailing twelve months NVCT reported a non-GAAP Earnings per Share(EPS) of -1.13. The EPS increased by 19.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -66.87% | ||
| ROE | -96.22% | ||
| Debt/Equity | 0 |
NVCT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to NVCT. The Buy consensus is the average rating of analysts ratings from 11 analysts.